Preservation of GHRH and GH-releasing peptide-2 efficacy in young men with experimentally induced hypogonadism

Preservation of GHRH and GH-releasing peptide-2 efficacy in young men with experimentally induced hypogonadism / Johannes D. Veldhuis, Daniel M. Keenan, Joy N. Bailey, John M. Miles, Cyril Y. Bowers

  • European Journal of Endocrinology 161 (2009) 2 (August), p. 293-300
  • PMID: 19458139
  • PMCID: PMC2772823
  • DOI: 10.1530/EJE-09-0270


Background: Somatostatin (SS), GHRH, GH-releasing peptide (GHRP), and the sex-steroid milieu regulate GH secretion.

Objective: To test whether GHRH and GHRP remain effective secretagogs in the face of short-term hypogonadism.

Design: Prospective, randomized double-blind.

Methods: Healthy young men (n=24) received a GnRH agonist twice 3 weeks apart followed by placebo (n=13, Pl) or testosterone (n=11, testosterone) addback.

Subjects: were then given consecutive i.v. infusions of l-arginine (to restrain SS outflow) and a maximally effective dose of GHRH or GHRP-2 (to test corresponding secretagog pathways).

Results: GH secretion stimulated by l-arginine/GHRH and by l-arginine/GHRP-2 was unaffected by combined testosterone/estradiol (E(2)) depletion. The low testosterone/E(2) milieu decreased basal (nonpulsatile) GH secretion (P=0.038), without altering fasting pulsatile GH secretion or IGF1 or IGF-binding protein (IGFBP)-3 concentrations. IGFBP-1 (P<0.0001) and abdominal visceral fat (AVF, P=0.017) correlated negatively with fasting basal GH secretion. By contrast, IGF1 (P=0.0012) and IGFBP-3 (P=0.015) correlated positively with fasting pulsatile GH secretion. AVF (P=0.0024) was a negative determinant, and IGF1 a positive determinant (P=0.018), of GHRH-driven GH pulses. Responses to GHRP-2 were unrelated to any of these factors.

Conclusion: l-arginine/GHRP-2 appears to be an especially robust stimulus of GH secretion, since efficacy is unmodified by profound short-term hypogonadism, a range of AVF estimates, and a spectrum of IGF1, IGFBP-1, and IGFBP-3 concentrations. Whether robustness also applies to chronic hypogonadism is not known.

Original document


Research / Study
1 August 2009
Bailey, Joy N.
Bowers, Cyril Y.
Keenan, Daniel M.
Miles, John M.
Veldhuis, Johannes D.
United States of America
Other organisations
Mayo Clinic College of Medicine and Science (MCCMS)
Doping classes
S1. Anabolic Agents
S2. Peptide Hormones, Growth Factors
GHRP-2 (pralmorelin)
Growth hormone (GH)
Growth Hormone Releasing Peptide (GHRP)
Growth hormone-releasing hormone (GHRH)
Medical terms
Health effects
Document category
Scientific article
Document type
Pdf file
Date generated
4 January 2022
Date of last modification
24 January 2022
  • Legal Source
  • Education
  • Science
  • Statistics
  • History
Country & language
  • Country
  • Language
Other filters
  • ADRV
  • Legal Terms
  • Sport/IFs
  • Other organisations
  • Laboratories
  • Analytical aspects
  • Doping classes
  • Substances
  • Medical terms
  • Various
  • Version
  • Document category
  • Document type
Publication period